ClinicalTrials.gg
Status unknownNCT05114603Updated May 3, 2022

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

A Phase 2 interventional study of HLX208 in Advanced Melanoma, sponsored by Shanghai Henlius Biotech. Status unknown at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
137th of 189
30 · median 50
Started
2022
with 24 others
Phase 2
75 of 203
30 open now
Registered
92nd of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 137th largest by planned enrollment of the 189 interventional ones that give a count, is one of 25 that started in 2022, is one of 75 in phase 2, and was the 92nd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation

03

Conditions studied

  • Advanced Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=18Y
  • Good Organ Function
  • Expected survival time ≥ 3 months
  • advanced melanoma with BRAF V600 mutation that have been diagnosed
  • score 0-1;

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with BRAF inhibitors or MEK inhibitors
  • Symptomatic brain or meningeal (unless the patient has beenon > treatment for 3 months, has no evidence of progress on imagingwithin 4 weeks prior to initial administration, and tumor-related clinicalsymptoms are stable).
  • Severe active infections requiring systemic anti-infective therapy
  • A history of other within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dose-escalation stage

    Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.

    Drug: HLX208

  • Experimental
    Dose-expansion stage

    Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.

    Drug: HLX208

Interventions

  • DrugHLX208

    level 1:600mg po Bid level 2:900mg po Bid

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review committee (IRRC) based on the e RECIST Version 1.1)

    Time frame: from first dose to the last patient was followed up for 6 month

Secondary outcomes

  1. PFS

    Progression-free survival(PFS):assessed by IRRC and the investigator based on the RECIST Version 1.1

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 1 years

  2. DOR

    Duration of response

    Time frame: from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first) assessed up to 1 years

  3. OS

    Overall survival

    Time frame: from the first dose to the time of death due to any cause,assessed up to 2 years

07

Study locations

2 of 7 sites recruiting
  • Peking University Cancer Hospita
    Peking, Beijing 100142, China
    Recruiting
  • Hunan cancer hospital
    Changsha, China
    Recruiting
  • West China Hospital of Sichuan University
    Chendu, China
    Not yet recruiting
  • Fujian cancer hospital
    Fujian, China
    Not yet recruiting
  • Shangxi Bethune Hospita
    Taiyuan, China
    Not yet recruiting
    • Huijing feng · Contact
  • union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
    Not yet recruiting
  • Henan cancer hospital
    Zhengzhou, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Aug 2023, 17 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 17 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 10, 2021
StartActual
Mar 21, 2022
Primary completionEst.
Aug 30, 2023
CompletionEst.
Aug 30, 2024
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05114603
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Mar 21, 2022
Primary completion
Aug 30, 2023 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
May 3, 2022

Study contacts

Jun Guo
Contact
guoj307@126.com
88196391
Lu Si
Contact
silu15_silu@126.com
88196391 ext. 88196391

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion